Corient Private Wealth LP acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,423 shares of the company's stock, valued at approximately $1,202,000. Corient Private Wealth LP owned approximately 0.05% of Prestige Consumer Healthcare at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PBH. AQR Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock valued at $2,558,000 after purchasing an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Prestige Consumer Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock valued at $2,535,000 after buying an additional 1,289 shares during the period. Goldman Sachs Group Inc. boosted its stake in Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock valued at $46,997,000 after buying an additional 120,965 shares in the last quarter. Jane Street Group LLC boosted its stake in Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock valued at $9,010,000 after buying an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after acquiring an additional 269 shares during the period. Institutional investors own 99.95% of the company's stock.
Prestige Consumer Healthcare Trading Down 0.7%
NYSE:PBH opened at $52.17 on Friday. The company has a market capitalization of $2.47 billion, a P/E ratio of 14.61, a P/E/G ratio of 1.65 and a beta of 0.33. The stock's 50 day moving average price is $50.76 and its 200 day moving average price is $54.14. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. Prestige Consumer Healthcare Inc. has a 52 week low of $42.62 and a 52 week high of $71.07.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. During the same period in the previous year, the company earned $0.90 EPS. The company's revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the stock. Weiss Ratings cut shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, June 25th. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a research note on Friday, May 15th. Oppenheimer cut shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a report on Thursday, May 14th. Finally, Zacks Research upgraded shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $70.75.
Check Out Our Latest Stock Analysis on Prestige Consumer Healthcare
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.
Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Articles
Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
